Showing results (141-150 of 300) with videos related to
Sort By:
Pageof 30
Cancers|June 18, 2020
Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?Luigi Pedone Anchora, Vittoria Carbone, Valerio Gallotta, et al.Journal of Cellular Physiology|April 27, 2011
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancerMarta De Donato, Marisa Mariani, Lella Petrella, et al.The British Journal of Radiology|September 22, 2015
Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation studyGabriella Macchia, Savino Cilla, Francesco Deodato, et al.Cancer Research|July 1, 2010
HuR regulates beta-tubulin isotype expression in ovarian cancerGiuseppina Raspaglio, Ilaria De Maria, Flavia Filippetti, et al.Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic processFrancesca Di Modugno, Valentina Caprara, Lidia Chellini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancerGabriella Ferrandina, Franco Oreste Ranelletti, Francesco Legge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patientsSimona Mozzetti, Cristiano Ferlini, Paola Concolino, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 3, 2020
Enhanced recovery after surgery (ERAS) in gynecology oncologyGiorgio Bogani, Giuseppe Sarpietro, Gabriella Ferrandina, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerGabriella Ferrandina, Manuela Ludovisi, Domenica Lorusso, et al.Oncotarget|December 18, 2015
miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinomaRosanna Sestito, Roberta Cianfrocca, Laura Rosanò, et al.Pageof 30